SOMAÍ and Universidade Lusófona publish peer-reviewed study to improve practices in the production of full-spectrum cannabis oils

SOMAÍ Pharmaceuticals, a multinational operator with EU-GMP certification, through a partnership with Universidade Lusófona, has published a peer-reviewed study in the prestigious journal 'Pharmaceuticals'. Entitled “Process Development for GMP-Grade Full Extract Cannabis Oil: Towards Standardized Medicinal Use“, the study describes an innovative process designed to produce pharmaceutical-grade Full Extract Cannabis Oil (FECO) that delivers consistency, efficacy and patient appeal.

This collaboration between SOMAÍ and Universidade Lusófona, one of Portugal’s largest private academic institutions, sends a bold message: that full-spectrum cannabis oil can offer a degree of control and reproducibility comparable to other pharmaceutical products, discrediting long-held industry assumptions.

Breakthrough in EU-GMP Cannabis Oil Production

This study aims to analyze the EU-GMP cannabis oil production process, as well as its evolution and results. The study published focuses on SOMAÍ’s proprietary and patent-pending methodology for extracting and refining cannabis oil. The uniqueness of this process lies in its ability to preserve the overall phytochemical integrity of the cannabis plant, encompassing cannabinoids and terpenes, while ensuring pharmaceutical-grade precision.

This scientific study claims that cannabis oil does not need to compromise on quality or standardization to preserve its full-spectrum properties.

Standardized full-spectrum extracts: a scientific breakthrough

Unlike unrefined extracts that often degrade the plant’s natural compounds, SOMAÍ’s advanced process utilizes refrigerated ethanol extraction followed by meticulous terpene preservation and purification techniques. This method keeps the plant’s original cannabinoid and terpene profile intact, delivering a truly full-spectrum cannabis oil with a consistent composition from batch to batch.

Key innovation highlights:

• Preservation of natural terpenes: SOMAÍ extraction retains the authenticity of the terpenes from the original cannabis flower;
• Scientific Terpene Reintroduction: Instead of guesswork, the terpene profile can be precisely controlled and reintroduced, making formulation a science-based process.

Improving patient experience: Taste, color and tolerability

In addition to laboratory metrics, patient experience is crucial. The study included sensory analyses that compared SOMAÍ’s purified FECO with unrefined cannabis extracts and competitor products. The results were compelling: patients consistently rated SOMAÍ’s oil as superior in terms of taste, color, aroma, and overall appeal.

This means that patients are more likely to tolerate and comply with treatment protocols using SOMAÍ’s FECO – an important consideration in the therapeutic applications of cannabis.

SOMAÍ Founder and Interim CEO Michael Sassano, highlighted the implications of the study for the sector in question:

“This research proves that full-spectrum cannabis oil can be pharmacologically accurate and reproducible. The outdated belief that full-spectrum means inconsistent or unregulated is no longer valid. SOMAÍ’s process bridges the gap between pharmaceutical science and botanical medicine in a way no one has done before.”

Sassano’s statement reflects a broader movement within the cannabis industry to elevate full-spectrum products, from artisanal blends to validated medical therapies.

Scientific rigor in medicinal cannabis: A university perspective

Maria do Céu Costa, Professor at Lusófona University and co-author of the study, also highlighted the broader scientific impact:

“Our findings confirm that with the right methodology, it is possible to preserve the plant’s therapeutic compounds while achieving pharmaceutical consistency and safety. This study brings medicinal cannabis closer to conventional healthcare, aligning it with scientific and regulatory expectations.”

The research underscores Lusófona’s commitment to advancing academic contributions to cannabis pharmacology, paving the way for greater collaboration between academia and the cannabis industry.

A new standard for cannabis-based medicines

SOMAÍ’s approach offers a stark contrast to conventional cannabis extracts produced without quality assurance or regulatory oversight. Their process is:

• Compliance with EU-GMP standards;
• Batch tested and validated;
• Scientifically reproducible;
• Pharmacologically stable;

The study by SOMAÍ and Universidade Lusófona, subject to peer review, not only represents a technological advance, but also a declaration that cannabis-based medicine can, and should, reach the highest standards of pharmaceutical development.

By combining cutting-edge extraction technology, terpene science and sensory validation, SOMAÍ is leading a transformation in the way full-spectrum cannabis oils are produced, regulated and prescribed.

As the global medical cannabis market grows, studies like this set a new standard of excellence – bringing credibility, safety and consistency to therapies derived from nature’s most complex plant.

____________________________________________________________________________________________________

____________________________________________________________________________________________________

What do you do with €3 a month? Become one of our Patrons! If you believe that independent cannabis journalism is necessary, subscribe to one of the levels of our Patreon account and you will have access to unique gifts and exclusive content. If there are many of us, we can make a difference with little!

João Xabregas

More postsBio

With a professional background in CAD technical drawing (2D and 3D), João Xabregas is an activist and advocate for all uses and applications of cannabis. He discovered and entered the world of cannabis during his youth, where he developed a special interest in the cultivation of the plant, which led him on a journey of self-learning through the world of cannabis that continues to this day. His adventures linked to cannabis cultivation began with the same goal as many others: to be able to guarantee the quality and eliminate any possible risks to his health of what he consumed, as well as to avoid any type of dependence on the illicit market. However, he quickly began to view the world of cannabis and everything related to it with a very different perspective. He admits the enormous passion he has for the most persecuted plant in the world and about which he is always willing to write and have a good conversation.

• João Xabregas

  https://cannareporter.eu/author/joaoxabregas/

  Cannabizetol: New cannabinoid may have antioxidant and anti-inflammatory benefits for the skin
• João Xabregas

  https://cannareporter.eu/author/joaoxabregas/

  Study reveals that inability to drive after using cannabis can last more than five hours
• João Xabregas

  https://cannareporter.eu/author/joaoxabregas/

  Systematic review and meta-analysis demonstrate the potential of CBD in reducing seizure frequency in Epilepsy
• João Xabregas

  https://cannareporter.eu/author/joaoxabregas/

  Portugal: New cannabis seizure in Grândola exposes yet another illegal trafficking operation disguised as a medicinal facility